NCT00535236View on ClinicalTrials.gov

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

PHASE1CompletedINTERVENTIONAL

Enrollment

341

Participants

Timeline

Start Date

November 2, 2007

Primary Completion Date

January 25, 2010

Study Completion Date

January 26, 2010

Conditions

Herpes ZosterHerpes Zoster-related Complications

Interventions

BIOLOGICAL

V212

0.65 ml V212 in 4 dose regimen. Treatment period of 125 days

BIOLOGICAL

Placebo

0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00535236 - A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002) | Biotech Hunter | Biotech Hunter